- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.03. | Takeda's oncology execs sharpen focus after restructuring | ||
| 13.03. | Sotio takes up option on ADCs, Boehringer inks discovery pact | ||
| 13.03. | Hologen AI commits $430M to MeiraGTx Parkinson's gene therapy | ||
| 13.03. | Eye surgery specialist BVI Medical claims $1B capital raise | ||
| 13.03. | ImmunoPrecise teases $10M ADC collab with major biotech | ||
| 12.03. | Clario acquires WCG's neuroscience-focused clinical outcome assessment business | ||
| 12.03. | GSK posts data on HIV assets vying for roles in 6-month combo | ||
| 12.03. | J&J's Monarch bronchoscopy robot cleared by FDA to connect to live CT scans | ||
| 12.03. | Insilico Medicine raises $110M for new trials and robotic helping hands | ||
| 12.03. | Manufacturer fuels Swiss biotech's next-gen vaccine portfolio in new investment deal | ||
| 12.03. | Harbour BioMed launches new obesity biotech on mission to preserve muscle mass | ||
| 12.03. | Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer | ||
| 12.03. | Roche pads out obesity pipeline, paying Zealand Pharma $1.6B upfront to codevelop amylin asset | ||
| 11.03. | NIH grants powered $94B in economic activity in 2024 and supported more than 400,000 jobs: report | ||
| 11.03. | Siemens Healthineers expands photon-counting CT family with new FDA clearances | ||
| 11.03. | Illumina aims to cut $100M in costs following China import ban | ||
| 11.03. | Daiichi taps Nosis to deliver RNA therapies beyond the liver | ||
| 11.03. | Pfizer, Arvinas post mixed breast cancer survival results in first phase 3 test for a PROTAC degrader | ||
| 11.03. | Coherus to lose 30% of staff as part of Udenyca sale to Accord | ||
| 10.03. | J&J opts out of licensing Genmab's Darzalex challenger after look at phase 1/2 data | ||
| 10.03. | With $200M in seed funding, Flagship-backed Lila Sciences touts ambitious AI vision | ||
| 10.03. | Beam gene therapy for protein deficiency passes early safety test, sets efficacy bar in space: analysts | ||
| 10.03. | Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort | ||
| 10.03. | Dexcom receives FDA warning letter over CGM manufacturing issues | ||
| 10.03. | Novo Nordisk links CagriSema to 16% weight loss, sending stock down again |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
